Evidence map›Paper›PMID 25031567›Full record

ArticleGenomics & informatics2014

New lung cancer panel for high-throughput targeted resequencing.

Eun-Hye Kim, Sunghoon Lee, Jongsun Park, Kyusang Lee, Jong Bhak, Byung Chul Kim

Open access · diamondAbstract read
In one paragraph

Article in Genomics & informatics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Eun-Hye KimTheragen Bio Institute, AICT, Suwon 443-270, Korea.
Sunghoon LeeTheragen Bio Institute, AICT, Suwon 443-270, Korea.
Jongsun ParkPersonal Genomics Institute, Genome Research Foundation, AICT, Suwon 443-270, Korea.
Kyusang LeeClinomics Inc., Seoul 138-961, Korea.
Jong BhakTheragen Bio Institute, AICT, Suwon 443-270, Korea. ; Personal Genomics Institute, Genome Research Foundation, AICT, Suwon 443-270, Korea.
Byung Chul KimPersonal Genomics Institute, Genome Research Foundation, AICT, Suwon 443-270, Korea. ; Clinomics Inc., Seoul 138-961, Korea.
Genome Research Foundation · KRTheragen · KRPreClinOmics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a new next-generation sequencing-based method to identify somatic mutations of lung cancer. It is a comprehensive mutation profiling protocol to detect somatic mutations in 30 genes found frequently in lung adenocarcinoma. The total length of the target regions is 107 kb, and a capture assay was designed to cover 99% of it. This method exhibited about 97% mean coverage at 30× sequencing depth and 42% average specificity when sequencing of more than 3.25 Gb was carried out for the normal sample. We discovered 513 variations from targeted exome sequencing of lung cancer cells, which is 3.9-fold higher than in the normal sample. The variations in cancer cells included previously reported somatic mutations in the COSMIC database, such as variations in TP53, KRAS, and STK11 of sample H-23 and in EGFR of sample H-1650, especially with more than 1,000× coverage. Among the somatic mutations, up to 91% of single nucleotide polymorphisms from the two cancer samples were validated by DNA microarray-based genotyping. Our results demonstrated the feasibility of high-throughput mutation profiling with lung adenocarcinoma samples, and the profiling method can be used as a robust and effective protocol for somatic variant screening.

Indexed as

high-throughput nucleotide sequencinglung neoplasmsnext-generation sequencingselector technologysomatic mutation screeningtarget enrichment

Identifiers

PMID25031567
PMCPMC4099348
OpenAlexW2107834937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.